Posts Tagged ‘Biotech’
100 new jobs and a new plant for Lonza in Visp
Lonza is expanding its partnership with an undisclosed major pharmaceutical company to supply antibody-drug conjugates (ADCs). This agreement includes building a new facility at Lonza’s Ibex® Biopark in Visp, Switzerland, and providing large-scale production of monoclonal antibodies for a new ADC treatment. Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical…
Read MoreSilvia Scherer, from APTISSEN SA, is Entrepreneur of the Year
On 4 October 2024, Silvia Sherer, co-founder of APTISSEN, became Swiss Entrepreneur of the Year in the category Industry, High-Tech & Life Sciences during a ceremony in Lucerne. Aptissen SA is a Geneva-based biomedical company specializing in the development and commercialization of innovative medical devices, primarily focused on treating osteoarticular conditions, such as…
Read MoreAtinary Technologies Announces Strategic Collaboration with Snapdragon Chemistry
Atinary Technologies has joined forces with Snapdragon Chemistry, a Cambrex subsidiary, to bring AI-driven automation into pharmaceutical process development By integrating Atinary’s no-code AI platform, SDLabs™, and Snapdragon’s LabOS™ software, the partnership has developed an automated Solid-Phase Oligonucleotide Synthesizer (SPOS), designed to optimize drug synthesis processes autonomously. This collaboration aims to improve efficiency…
Read MoreGenolier Innovation Hub – A Pioneer in Medical Innovation
The Genolier Innovation Hub was inaugurated this Friday 27 September in canton of Vaud. With a CHF 100 million investment, the site aims at fostering innovation in healthcare in the Swiss Health Valley and internationally. Positioned next to the Genolier clinic, the 25,000 square-meter building is designed to encourage interdisciplinary collaboration between research, industry,…
Read Moreten23 health Opens State-of-the-Art VIVA2® Sterile Manufacturing Facility in Visp
This advanced, energy-efficient plant will enhance the company’s capabilities in commercial and clinical manufacturing of sterile medicines, including vials, syringes, and cartridges. The Swiss CDMO celebrates the grand opening of its VIVA2® facility in Visp. The facility adds two production lines: Line 2, designed for large-scale filling of ready-to-use containers, and Line 3,…
Read More8 startups selected for the Future of Health Grant
The Future of Health Grant received a record-breaking 213 applications in response to its 5th call for projects. These included submissions from around 100 international startups, demonstrating the programme’s growing reputation abroad. 8 promising projects were selected to join the programme. Level 1 Digehealth (Zurich) : offers a 24/7 monitoring device for bowel…
Read MoreDebiopharm lays the foundation stone for its new building
The new building will have a surface area of 3,500m2 dedicated to the creation of 150 to 300 flexible workstations. It will enable the company to expand and develop. The work will be completed in 2026. The building will also house a reservoir containing a total of 4.5 million litres of water, which…
Read MoreTOP 100 Swiss Startup Award 2024
This year, 15 startups from the Swiss Health Valley we ranked in the prestigious TOP 100 Swiss Startup Award 2024, including HAYA Therapeutics at #5. The 14th ceremony of the TOP 100 Swiss Startup Award took place in Lausanne and was attended by a curated audience comprising startup founders, investors, and key partners…
Read MoreHAYA Therapeutics Announces $1 billion Collaboration with Lilly
The Biopôle-based biotech company and the American pharma giant partner to discover novel regulatory genome targets for obesity and related metabolic conditions using HAYA Therapeutics proprietary RNA platform HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, announced a multi-year agreement with Eli Lilly and Company to apply…
Read MoreLife Sciences account for 10% of the canton of Fribourg economy
According to a BAK Economy study, life sciences generated added value of over CHF 1.5 billion in 2023 and employed 3,300 full-time equivalents (FTEs). Through value chains, numerous companies in other economic sectors also benefit from the activities of the life sciences industry. Thus, a total added value of 1.96 billion francs, representing 10% of…
Read More